


Liver Cancer Markers




Liver cancer is largely a problem of the less developed regions where 83% (50% in China alone) of the estimated 782,000 new cancer cases worldwide occurred in 2012. It is the fifth most common cancer in men (554,000 cases, 7.5% of the total) and the ninth in women (228,000 cases, 3.4%). Liver cancer is the second most common cause of death from cancer worldwide, estimated to be responsible for nearly 746,000 deaths in 2012 (9.1% of the total). The prognosis for liver cancer is very poor (overall ratio of mortality to incidence of 0.95), and as such the geographical patterns in incidence and mortality are similar.


GLOBOCAN database



FFPE human liver tissue stained with anti-ABCB11 [10D4.1]




FFPE human HCC stained with anti-AFP [EP209]




FFPE human liver stained with anti-ARG1 [EP261]



FFPE human HCC stained with anti-GPC3 [GPC3/863]



FFPE human HCC stained with anti-HSA [OCH1E5]



FFPE human Tonsil stained with anti-PCNA [PC10]

Liver Cancer Markers

Name	Cat. No.	Application
ABCB1/MDR1 [D-11]	MC0195	Frequently overexpressed in liver cancer
ABCB1/MDR1 [EP271]	RM0295	
ABCB1/MDR1 [MD33R]	RM0336	
ABCB11/BRIC2 [10D4.1]	MC0118	ABCB11 deficiency may be at an increased risk of liver cancer
ABCB4/MDR3 Polyclonal	RC0009	ABCB4 deficiency causes cholestasis, and might be expected to cause cholangitis and predispose to liver cancer
AFP [C3]	MC0605	AFP expression usually indicates malignancy in a hepatocellular nodule and hepatocytic histogenesis of a malignancy
AFP [EP209]	RM0001	
Alpha-1-AT [AAT/1378]	MC0142	Increased level recognized as diagnostic and prognostic marker of HCC
Arginase-1/ARG-1 [EP261]	RM0279	Expressed in all hepatocytes throughout the lobule of normal liver (cytoplasm) and in HCC (cytoplasm or cytoplasm plus nucleus)
CA15.3/EMA [139H2]	MC0868	Expression and localization of CA15.3 proteins in primary liver carcinomas may act as prognostic markers, and CA15.3 molecules might be helpful in differentiation
CA15.3/EMA [E29]	MC0131	
CA15.3/EMA [EP85]	RM0133	
Cadherin-E [CDH1/1525]	MC0165	Impaired expression of Cadherin-E promotes hepatocellular carcinogenesis and is associated with a worse prognosis
Cadherin-E [EP6]	RM0088	
Catenin Beta [EP35]	RM0008	β -catenin loss may promote chemical carcinogenesis in the liver
CEA/CD66 [CEA31]	MC0523	May be useful in aiding the detection of early foci of gastric carcinoma and distinguishing pulmonary adenoca from mesothelioma
CEA/CD66 [COL-1]	MC0323	
CEA/CD66 [EP216]	RM0060	
CEACAM1/CD66a [28T25]	MC0147	Widely expressed in HBV-related HCC. Down-regulating CEACAM1 may indicate occurrence and progression of HBV-related HCC
Cyclin D1 [DCS-6]	MC0732	Downregulation might be associated with prognosis of liver cancer
Cyclin D1 [EP12]	RM0071	
CK [CAM 5.2]	MC0526	Useful marker for neoplasms of epithelial differentiation negative in SCC but positive in sebaceous carcinoma and basal cell carcinoma)
CK10 [EP97]	RM0073	Useful in differentiating squamous carcinomas and adenocarcinomas
CK10 [LH2]	MC0737	
CK18 [DC10]	MC0112	
CK18 [DE-K18]	MC0741	In neoplastic tissues, Useful to aid in the identification of adenocarcinomas and some squamous cell carcinomas
CK18 [EP30]	RM0078	
CK19 [BA17]	MC0529	Not expressed in most hepatocytes, thus is useful in the identification of liver metastasis and can be used in a panel with HSA
CK19 [EP72]	RM0079	
CK19 [RCK108]	MC0113	
CK8/18 [EP17/EP30]	RM0066	In neoplastic tissues, Useful to aid in the identification of adenocarcinomas and some squamous cell carcinomas
CK8/18 [K8.8&DC10]	MC0764	

Medaysis

Liver Cancer Markers

Name	Cat. No.	Application
CK LMW [KRTL/1077]	MC0769	In neoplastic tissues, Useful to aid in the identification of adenocarcinomas and some squamous cell carcinomas
EGFRvIII [MD17]	MC0535	EGFRvIII may promote HCC invasion
Ep-Cam [Ber-EP4]	MC0334	A useful marker for most epithelial cancers such as HCC except RCC, urothelial carcinoma and SCC
Ep-Cam [EP155]	RM0091	
Glypican-3 [1G12]	MC0281	Expression in HCC but not in non-neoplastic hepatic tissue, making it a useful marker for HCC
Glypican-3 [GPC3/863]	MC0792	
HSP70 [W27]	MC0672	A potential biomarker for HCC diagnosis, and a combination with p53 may improve diagnostic accuracy
HSA (Hep Par-1) [EP265]	RM0286	Useful in differentiating HCC with adenoid features from adenoca, either primary in the liver or metastatic lesions to the liver
HSA (Hep Par1) [OCH1E5]	MC0365	
IGF-I Receptor β [MD30R]	RM0333	May be a liver reserve assessment tool in HCC
Ki67 [EP5]	RM0116	May be a prognostic marker in patients with HCC
Ki67 [MIB-1]	MC0185	
Ki67 [SP6]	RM0255	
p53 [BP-53-12]	MC0218	A potential biomarker for HCC diagnosis, and a combination with HSP70 may improve diagnostic accuracy
p53 [DO-7]	MC0219	
p53 [EP9]	RM0154	
PCNA [EP91]	RM0158	May be used to differentiate HCC (significantly increased PCNA-LI) from the benign categories
PCNA [MD38R]	RM0341	
PCNA [PC10]	MC0238	

Research Use Only